Xilio Therapeutics (XLO) Shares Outstanding (2020 - 2026)

Xilio Therapeutics has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $16.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 206.38% year-over-year to $16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 206.38% YoY) and the FY2025 annual result came in at $8.4 million, up 155.76% from the prior year.
• Shares Outstanding (Entity) grew to $16.3 million in Q1 2026 per XLO's latest filing, from $8.4 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $16.3 million in Q1 2026 and troughed at $2.0 million in Q1 2022.
• A 5-year average of $4.5 million and a median of $2.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) jumped 3689.73% in 2022, then rose 0.23% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $2.0 million in 2022, then gained by 0.66% to $2.0 million in 2023, then soared by 65.74% to $3.3 million in 2024, then jumped by 155.76% to $8.4 million in 2025, then jumped by 95.57% to $16.3 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $16.3 million, $8.4 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.